Real-World Determinants of Olanzapine Prescribing for Antiemetic Prophylaxis in Adults Receiving Highly-Emetogenic Chemotherapy
Soroush Fariman, Haneul Gil, Kevin Chen, Jacob N Stein, Jennifer Elston Lafata · 2025
Read Real-World Determinants of Olanzapine Prescribing for Antiemetic Prophylaxis in Adults Receiving Highly-Emetogenic Chemotherapy by Soroush Fariman, Haneul Gil, Kevin Chen, Jacob N Stein, Jennifer Elston Lafata (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12708303.txt.
Description
Soroush Fariman, Haneul Gil, Kevin Chen, Jacob Stein, and Jennifer Elston Lafata wrote this 2025 study on why a nausea drug is often left out of cancer care plans. Since 2017, guidelines urge a four-drug shield against sickness for patients on the harshest chemo drugs. The fourth drug, olanzapine, is the one most often skipped, and the team asked what drives that gap.
Records from a North Carolina cancer center and its linked clinics covered 878 adults who began such chemo in 2022. All had orders for the three base drugs, but only about a third had the fourth drug ordered in the month around the first dose. Orders lagged most for breast, gut, and several other cancer types when set against blood cancers. The authors read the gap as a target for clinic-level fixes rather than patient choice.
Catalog record
| CREATOR | Soroush Fariman, Haneul Gil, Kevin Chen, Jacob N Stein, Jennifer Elston Lafata |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |